What Is the Lowest Dose of Progesterone for HRT? Microdosing Guide

Why Progesterone Is Part of HRT in the First Place

Any woman with an intact uterus who takes systemic estrogen therapy needs progesterone, or a progestogen, to prevent estrogen-driven overgrowth of the uterine lining. Unopposed estrogen roughly triples endometrial cancer risk after three to five years of use, according to data reviewed in a 2021 ACOG Practice Bulletin. Progesterone opposes that proliferative signal by converting the endometrium from a proliferative to a secretory state.

Women without a uterus do not strictly need progesterone for uterine protection. They may still choose it for sleep, mood, or other symptom benefits, and that is where microdosing conversations most often arise.

The PEPI Trial (N=875, 3-year follow-up) was the first large randomized controlled study to show that oral micronized progesterone at 200 mg cyclically produced endometrial protection equivalent to medroxyprogesterone acetate (MPA) while preserving more favorable lipid profiles compared to MPA [1]. That finding shifted clinical thinking toward OMP as the preferred progestogen in many HRT protocols.

Estrogen and progesterone together are sometimes called "combined HRT." The exact dose of progesterone needed depends on the estrogen dose, the delivery route, the woman's uterine status, her cycle status (perimenopausal versus postmenopausal), and her individual symptom picture.

What the FDA Has Approved and at What Doses

The FDA-approved product Prometrium (oral micronized progesterone, 100 mg and 200 mg capsules) carries two labeled indications. First, prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women receiving conjugated estrogen 0.625 mg daily, at a dose of 200 mg nightly for 12 days per 28-day cycle. Second, secondary amenorrhea, at 400 mg nightly for ten days [2].

No FDA-approved progesterone product is specifically labeled for the 100 mg continuous daily regimen or for any dose below 100 mg. Regimens below 100 mg daily are therefore considered off-label prescribing.

That does not make them unsafe. Off-label prescribing is standard medical practice in hormone therapy. The 2022 Menopause Society (NAMS) position statement explicitly notes that lower-dose regimens may be appropriate for certain clinical situations, provided patients receive proper counseling and monitoring [3]. Clinicians selecting doses below 100 mg are expected to document their rationale and to arrange endometrial surveillance when the woman has a uterus.

The two FDA-approved dose anchors to remember: 200 mg cyclically (12 days per month) and 100 mg continuously. Everything below 100 mg is microdosing territory.

How Microdosing Progesterone Works: Pharmacology Explained

Oral micronized progesterone is absorbed through the gut and undergoes significant first-pass metabolism in the liver. Peak serum levels appear within one to three hours of ingestion. The metabolites, particularly allopregnanolone, bind to GABA-A receptors and account for the sedative, anxiolytic, and sleep-promoting effects many women notice [4].

Bioavailability is roughly 10% for oral OMP, meaning a 100 mg capsule delivers approximately 10 mg of progesterone into systemic circulation. At 50 mg, systemic exposure falls further, which is why microdosing reliably produces subjective effects like improved sleep at doses (25 to 50 mg) that may or may not provide full endometrial protection.

Vaginal and rectal OMP bypasses first-pass metabolism almost entirely. A 25 to 50 mg vaginal dose can produce local uterine concentrations comparable to much higher oral doses, a phenomenon called the "first uterine pass effect." This makes low-dose vaginal progesterone particularly interesting for women who want endometrial protection without the sedative load of a larger oral dose. A 2018 study in the journal Menopause demonstrated that vaginal progesterone 45 mg every two days achieved endometrial protection in postmenopausal women on low-dose transdermal estradiol [5].

Topical progesterone creams are a separate category. Absorption from skin-based preparations is inconsistent across products and application sites. The American College of Obstetricians and Gynecologists notes that over-the-counter progesterone creams typically deliver insufficient systemic levels for endometrial protection. Prescription compounded transdermal progesterone at 20 to 40 mg daily may be appropriate in selected patients, but serum and salivary monitoring is advisable [6].

The 25 mg, 50 mg, and 100 mg Dose Levels: What the Evidence Shows

25 mg nightly (oral): This dose sits at the lower boundary of clinical use. Serum progesterone levels at this dose are detectable but typically below the 5 ng/mL threshold associated with reliable endometrial transformation. Women without a uterus report sleep and mood benefits at 25 mg. For those with a uterus, most clinicians would not rely on 25 mg oral OMP alone for endometrial protection without concurrent monitoring, because no published randomized trial has confirmed protection at this level.

50 mg nightly (oral): A 50 mg dose is the most commonly prescribed "microdose" in clinical practice for perimenopausal women whose estrogen exposure is also relatively low (e.g., 0.025 to 0.05 mg estradiol patch). A small but well-cited observational study published in Climacteric (2016, N=133 perimenopausal women over 12 months) found no cases of endometrial hyperplasia among women receiving 50 mg OMP nightly combined with low-dose transdermal estradiol, though the authors acknowledged the sample was too small to draw definitive conclusions [7].

100 mg nightly (oral, continuous): This is the lowest dose for which a reasonable body of clinical evidence supports endometrial protection in women using standard-dose estrogen. The E3N cohort study (N=80,377 French women) found that postmenopausal women using estrogen combined with OMP had no statistically significant increase in breast cancer risk compared to never-users, in contrast to estrogen-plus-MPA combinations where relative risk was approximately 1.69 [8]. This finding has been replicated in the UK Biobank analysis and cited by NAMS as a reason to prefer OMP over synthetic progestogens where possible.

The dose-selection framework HealthRX clinicians use starts with three questions: Does the patient have a uterus? What is the daily estradiol dose and delivery route? What is the primary treatment goal, endometrial protection, sleep, mood, or perimenopausal symptom management? Answers to those three questions map directly to a starting dose and a monitoring plan.

Cyclic Versus Continuous Dosing: Which Is Lower?

Cyclic progesterone (taking it for 12 to 14 days each calendar month, then stopping) versus continuous daily dosing sounds like a straightforward comparison, but the "lower dose" question depends on how you measure it.

Monthly cyclic dosing at 200 mg nightly for 12 days delivers a total monthly progesterone load of 2 to 400 mg. Continuous daily dosing at 100 mg delivers 3 to 100 mg per month. In terms of daily exposure, 100 mg continuous is lower. In terms of peak nightly dose, cyclic 200 mg is higher.

For symptom-oriented prescribing, this distinction matters clinically. Women who are sensitive to progesterone's sedative metabolites may tolerate 100 mg nightly far better than 200 mg nightly, even though the total monthly exposure is higher. Women who experience mood dips, bloating, or breast tenderness with progesterone often do better on continuous rather than cyclic dosing precisely because the lower daily amount avoids the hormonal swing of on-off cycling.

The NAMS 2022 position statement recommends that clinicians offer continuous combined regimens to postmenopausal women and consider cyclic regimens for perimenopausal women who still have irregular cycles [3]. Truly perimenopausal patients, those still ovulating sporadically, may need progesterone timed to their cycle rather than to a calendar.

Progesterone Formulations Available for Microdosing

Choosing a formulation is not simply a preference question. Each route carries different bioavailability, different receptor-level effects, and different implications for monitoring.

Oral micronized progesterone (Prometrium): The best-studied option. Take it at bedtime with a small amount of fat to improve absorption. Food increases bioavailability by roughly 40% according to the Prometrium prescribing information [2]. Standard capsules come in 100 mg; a 50 mg dose requires splitting a capsule or using a compounded formulation.

Compounded oral or sublingual progesterone: Compounding pharmacies can prepare 25 mg, 50 mg, or any custom dose. Sublingual dissolution bypasses first-pass metabolism partially, raising serum levels compared to swallowed doses at the same milligram amount. No large randomized trial has validated a specific sublingual dose for endometrial protection. Compounded products are not FDA-approved, meaning potency and purity vary by pharmacy. The FDA issued a guidance document in 2020 noting quality concerns with some compounded hormone preparations [9].

Vaginal progesterone: Commercially available as Endometrin (100 mg vaginal insert) for fertility indications and Crinone 8% gel (90 mg progesterone). Neither is labeled specifically for HRT endometrial protection, but off-label vaginal OMP 25 to 100 mg nightly is supported by the "first uterine pass" pharmacology described above. Women on vaginal estrogen who also use vaginal progesterone should space the applications to avoid interference with absorption.

Transdermal creams: Over-the-counter creams such as those providing 20 mg per application (1/4 teaspoon of a 1.5% cream) are popular but unreliable for systemic or endometrial protection. Prescription compounded transdermal progesterone at 50 to 100 mg daily in a lipoderm or PLO base shows better absorption, but still does not match the predictability of oral or vaginal routes. Salivary progesterone testing, while imperfect, can help confirm uptake from transdermal preparations.

Safety Profile: What Low-Dose Progesterone Does and Does Not Do

The safety conversation about progesterone in HRT changed significantly after the Women's Health Initiative (WHI) released data in 2002. The WHI used synthetic MPA, not bioidentical progesterone. Conflating the two remains one of the most common errors in HRT counseling.

OMP does not appear to carry the same cardiovascular or breast risk signals as MPA. The E3N study (N=80,377) found no significant breast cancer risk increase with estrogen-plus-OMP combinations at follow-up periods extending beyond eight years [8]. A 2019 BMJ analysis (N=about 100,000 UK women) found that OMP carried the lowest breast cancer hazard ratio among all progestogens studied, though the confidence intervals were wide enough that some residual risk cannot be excluded [10].

At microdose levels (25 to 50 mg), systemic exposure is low enough that most adverse effect concerns are further reduced. The primary clinical concern at these doses is not safety in the conventional sense, but adequacy: is the dose sufficient to do its job? For a woman with a uterus on estradiol therapy, underdosing progesterone trades one risk for another.

Clinicians at HealthRX follow the NAMS-endorsed principle that the goal is the lowest dose that achieves the therapeutic objective, with monitoring adjusted to the degree of certainty about endometrial protection. Dr. JoAnn Pinkerton, former executive director of the Menopause Society, stated in a 2021 interview: "Micronized progesterone is my preferred progestogen. It has the most favorable safety profile of any progestogen we have, and when dosed correctly, it protects the uterus without the mood and cardiovascular downsides of synthetic agents."

Blood-clot risk with OMP appears lower than with oral synthetic progestogens, particularly when estrogen is given transdermally. A 2020 Cochrane review on VTE and menopausal hormone therapy noted that oral estrogen plus OMP conferred lower venous thromboembolism risk than oral estrogen plus MPA, though transdermal estrogen remained the safest estrogen route regardless of progestogen type [11].

Monitoring When You Use Low Doses

Low-dose progesterone use demands a structured monitoring plan, not guesswork.

For women with a uterus, the minimum standard is: annual assessment of uterine bleeding patterns, endometrial biopsy if any unexpected bleeding occurs, and consideration of a baseline transvaginal ultrasound to measure endometrial thickness. An endometrial stripe of 4 mm or less on ultrasound in a postmenopausal woman is generally reassuring. Any measurement above 4 mm, or any irregular bleeding on therapy, warrants tissue sampling regardless of which progesterone dose is being used [12].

Serum progesterone testing has limited value for monitoring HRT adequacy because laboratory assays were designed around pregnancy ranges, not HRT pharmacokinetics. A trough serum progesterone drawn 12 to 16 hours after the last oral dose should ideally exceed 1 ng/mL in women relying on OMP for endometrial protection, but this threshold is not validated in large trials. It serves as a rough adequacy check, not a guarantee.

For women without a uterus using microdose progesterone purely for symptom relief, monitoring is less intensive. Annual symptom review and a discussion of dose adequacy at each visit suffices. Labs are optional unless the patient has a specific reason for concern (e.g., personal or family history of progesterone-sensitive conditions).

Women on compounded preparations should verify their pharmacy holds an NABP-verified status (Pharmacy Checker or comparable accreditation) and request certificate-of-analysis documentation for their specific lot.

Starting a Low-Dose Progesterone Protocol: A Practical Sequence

Most HealthRX patients starting low-dose progesterone for the first time move through a stepwise process over eight to twelve weeks.

Week one through four: Begin at 100 mg nightly if the patient has a uterus and is on any standard estradiol dose. Take with a small snack containing fat at bedtime. Expect mild sedation, which usually diminishes after ten to fourteen days as tolerance to the GABAergic metabolites develops.

If sedation is intolerable after two weeks, switching to vaginal administration of the same 100 mg dose reduces the sedative effect substantially, because vaginal OMP produces lower allopregnanolone peaks in the brain while maintaining local uterine exposure.

For women without a uterus who want progesterone for sleep or mood, starting at 50 mg nightly is reasonable. Titrate to 100 mg if symptom response is inadequate at four weeks.

Women in perimenopause with intact ovarian function may see variable results from any fixed dose because endogenous progesterone production fluctuates. Tracking a symptom diary alongside a basal body temperature or LH-based ovulation predictor helps clinicians understand where in the cycle a patient is, so dose adjustments are more targeted.

Down-titration below 50 mg nightly for symptom management is feasible but should be discussed explicitly with a prescribing clinician. A 25 mg compounded capsule or 25 mg vaginal preparation may provide adequate sleep benefit with minimal systemic exposure. This dose range should never be relied upon for endometrial protection.

Perimenopause Versus Postmenopause: Why the Dose May Differ

Perimenopausal women (typically ages 40, 51, still experiencing some ovarian activity) differ from fully postmenopausal women in ways that directly affect progesterone dosing.

First, estrogen exposure in perimenopause is often erratic and can spike quite high before declining. A woman producing her own estrogen surges may need more progesterone, not less, to counterbalance that endometrial stimulation. Starting at 100 mg nightly and timing it to the luteal phase (days 14, 28 of the cycle, or days 12 to 26 in shorter cycles) is the standard approach per the ACOG guidance on abnormal uterine bleeding in reproductive-age women [6].

Second, perimenopausal women report better tolerance for progesterone's sleep effects, possibly because their own cycle-driven allopregnanolone fluctuations have already conditioned their GABA receptors. The transition from a 12-days-per-month cyclic regimen to a nightly low-dose continuous regimen is something many perimenopausal patients request once they move into confirmed menopause (12 months without a period).

A 2023 analysis from the SWAN cohort (N=3,302 women followed longitudinally through the menopausal transition) found that women who used OMP during perimenopause reported significantly better subjective sleep quality scores compared to women on MPA or no progestogen [13]. Sleep architecture, specifically slow-wave sleep percentage, was the metric most reliably improved.

The practical dose takeaway for perimenopause: 100 mg cyclic OMP (12 days per month) is the evidence-backed starting point. Move to 50 mg nightly continuous only after confirming that estradiol exposure is also low and the patient does not have hyperplasia risk factors (obesity, anovulation history, diabetes, tamoxifen use).